If you’re living with chronic graft-versus-host disease (GVHD) — or supporting someone who is — you know this condition rarely affects just one part of the body. When symptoms involve the skin, joints ...
Graft-versus-host disease (GVHD) following liver transplantation remains a rare but devastating complication, characterised by donor immunocompetent cells initiating an immune attack against host ...
The European Medicines Agency (EMA) has recommended the refusal of marketing authorization for Rezurock (belumosudil) for treating patients 12 years or older with chronic graft-vs-host disease (cGvHD) ...
Fred Hutch bone marrow transplant and GVHD expert Dr. Geoffrey Hill explains how a new approach has changed the BMT landscape, where research is headed next Now, more than 1.5 million transplants have ...
Hosted on MSN
What To Know About Graft vs. Host Disease (GVHD)
Graft vs. host disease (GVHD) can occur after a stem cell transplant from a donor. Transplants replace unhealthy cells with healthy blood-forming cells, which can treat some cancers. GVHD happens when ...
Hematopoietic cell transplantation (HCT), also known as bone marrow transplantation, is a critical treatment for blood cancers such as leukemia, lymphoma, and myeloma, as well as certain genetic and ...
Hematopoietic stem cell transplantation (HSCT) remains a vital treatment for a variety of haematologic malignancies and non‐malignant disorders. The procedure, involving the transfer of multipotent ...
Overall survival in hematopoietic stem cell transplant patients with hematologic malignancies: Accounting for the unobserved risk factors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
MiNK Therapeutics receives an NIAID grant to develop iNKT cell therapies for preventing graft-versus-host disease in stem cell transplants. MiNK Therapeutics, Inc., a biopharmaceutical company ...
Refined response (RR) criteria for acute graft-vs-host disease (GVHD) showed improved predictive performance over conventional criteria, with higher area under the curve (AUC) values and negative ...
Paris, October 17, 2025. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion on the marketing authorisation application for Rezurock ...
Impact of radiation dose in multi-isocentric volumetric arc-based total body irradiation on oncological outcomes in allogenic stem cell transplantation. Chi-square analysis showing predictors of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results